Target
doxorubicin
30 abstracts
Abstract
Ex vivo assessment of cellular mass response for personalized therapy selection of hyperthermic intraperitoneal chemotherapy (HIPEC) agents.Org: Travera, Medford, MA,
Abstract
Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.Org: GEICO, Arcagy-Gineco, NSGO-CTU, SAKK, BGOG,
Abstract
Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.Org: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital),
Abstract
Randomized controlled, open-label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma.Org: Mannheim University Medical Center (UMM), Istituto Nazionale Tumori Pascale, Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone",
Abstract
Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial: Mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in older patients with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression.Org: Istituto Europeo Oncologia, Community Health Network, Inc, Wielkopolskie Centrum Onkologii, Department of Obstetrics and Gynecology, Faculty of Medicine,
Abstract
Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials.Org: Concr LTD, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow,
Abstract
Real-world comparison: Neoadjuvant pembrolizumab (pembro-NACT) vs. dose-dense neoadjuvant chemotherapy (ddNACT) in early stage triple-negative breast cancer (TNBC).Org: Zucker School of Medicine,
Abstract
Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.Org: Hospital Sant Joan de Deu,
Abstract
A randomized, multicenter, open-label phase III trial of hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer (KOV-HIPEC-02).Org: Inje University Busan Paik Hospital, Seoul St Mary’s Hospital, Pusan Yangsan National University Hospital, Soonchunhyang University Cheonan Hospital, Seoul Metropolitan Government Seoul National University Boramae Medical Center,
Abstract
Rituximab, chidamide, and zanubrutinib (ZCR) ± CHOP as a regimen for treatment naive (TN) double-expressor DLBCL (DE-DLBCL).Org: Affiliated Dongguan People’s Hospital, Dongguan People’s Hospital,
Abstract
Phase 2a results of SQ3370, a doxorubicin-based click chemistry therapeutic in patients with advanced STS: Planned interim analysis.Org: Shasqi Inc.,
Abstract
Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial.Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, DFCI/PCC Fellowship Program - Attendings, Personalis, Inc.,
Abstract
Predictive cytokine biomarkers for immune-related adverse events associated with immune checkpoint inhibitor therapy in Hodgkin lymphoma.Org: NYU Langone Medical Center, NYU Langone Health, New York, NY, Perlmutter Cancer Center, New York University Langone Health,
Abstract
Effect of fructose on anthracycline and HER-2 blocking agent mediated cardiotoxicity through NLRP3 and MyD88 mediated pathways: New roles of sweeteners in cardio-oncology.Org: Fondazione G. Pascale, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar Di Valpolicella,
Abstract
Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity.Org: Division of Cardiology, Naples, Italy, Division of Cardiology, Azienda USL Toscana Nord-Ovest, Versilia Hospital, Lido Di Camaiore, Italy, Servizi Cardiologici Integrati, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, Sperimentazione Animale, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy, Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy,
Abstract
Patient-derived 3D bioprinting pan-cancer drug screening platform for personalized medicine.Org: Department of Liver Surgery, Peking Union Medical College Hospital, Beijing, China, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Department of Physiology, Institute of Basic Medical Sciences, CAMS, Beijing, China, Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China, Department of Head and Neck Surgical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China,
Abstract
Effect of 1-L-MT on immunotherapy of diffuse large B-cell lymphoma via downregulation of PD-L1.Org: Shandong Provincial Qianfoshan Hospital,
Abstract
Update on GALLANT: A phase 2 study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab in previously treated sarcoma (NCT04535713).Org: Sarcoma Oncology Research Center, Santa Monica, CA, Sarcoma Oncology Center,
Abstract
Treatment of focal anaplastic Wilms tumor (FAWT): A report from the Children’s Oncology Group (COG) AREN0321 and AREN03B2 studies.Org: Washington University in St Louis, University of Southern California, Los Angeles, CA, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Michigan Hospital, Uniformed Services University of the Health Sciences,
Abstract
Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS).Org: Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Department of Medicine, Icahn School of Medicine at Mount Sinai, Sarcoma Medical Oncology Service,
Abstract
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.Org: Levine Cancer Institute, Wilmot Cancer Institute, BC Cancer Centre for Lymphoid Cancer, Willamette Valley Cancer Institute and Research Center, US Oncology Research,
Abstract
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.Org: University of California San Diego Medical Center, La Jolla, CA, Wake Forest University School of Medicine, University of California San Francisco, University of Rochester Medical Center Department of Medical Oncology, University of Alabama at Birmingham Department of Hematology, Birmingham, AL,
Abstract
Safety and efficacy of PIPAC in ovarian cancer patients with peritoneal metastases: A first-in-US phase I study.Org: City of Hope National Medical Center, City of Hope Medical Group, City of Hope Cancer Center, City of Hope Comprehensive Cancer Center, City of Hope National Comprehensive Cancer Center,
Abstract
Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.Org: IRCCS Ospedale Pediatrico Bambino Gesu, University College London Hospitals NHS Foundation Trust, Hospital Universitari Vall d Hebron, Regina Margherita Childrens Hospital and University of Turin, Turin, Italy, Princess Máxima Centrum,
Abstract
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, Seagen, Inc.,
Abstract
Clinical implications of recurring mutations in myxoid liposarcoma (MLS).Org: University of Texas MD Anderson Cancer Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center,
Abstract
Building liquid-liquid perfusion interface (LLPI) –based patient-derived tumoroids (PDTs) model system as clinical research tools for testing cancer therapeutics.Org: Spanios, Houston, TX, Idaho State University, Pocatello, ID,
Abstract
External validation of venous thromboembolism risk prediction models in patients with multiple myeloma in a community setting: A retrospective cohort study.Org: Saint Vincent Hospital Cancer Center Green Bay, University of Pittsburgh Medical Center Cancer Center, Saint Vincent Cancer and Wellness Center, Saint Vincent Hospital, Department of Hematology/Oncology, Internal Medicine, St. Vincent Hospital,
Abstract
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.Org: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, Dana-Farber Cancer Institute, Boston, MA, USA, Moffitt Cancer Center and Research Institute, Tampa, FL, Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain, University of Lille, Centre Hospitalier Universitaire, Lille, France,
Abstract
A phase ll study on the neoadjuvant treatment of resectable high-risk soft tissue sarcoma with anlotinib and doxorubicin.Org: Henan Cancer Hospital, Zhengzhou Gensciences,